Research Output per year
Fingerprint Fingerprint is based on mining the text of the person's scientific documents to create an index of weighted terms, which defines the key subjects of each individual researcher.
- 13 Similar Profiles
gemcitabine
Medicine & Life Sciences
Pancreatic Neoplasms
Medicine & Life Sciences
temozolomide
Medicine & Life Sciences
Adenocarcinoma
Medicine & Life Sciences
Lymphoma
Medicine & Life Sciences
Drug Therapy
Medicine & Life Sciences
Radiotherapy
Medicine & Life Sciences
Survival
Medicine & Life Sciences
Network
Recent external collaboration on country level. Dive into details by clicking on the dots.
Research Output 1991 2018
1
Citation
(Scopus)
An Italian cost-effectiveness analysis of paclitaxel albumin (nab-paclitaxel) + gemcitabine vs gemcitabine alone for metastatic pancreatic cancer patients: the APICE study
Lazzaro, C., Barone, C., Caprioni, F., Cascinu, S., Falcone, A., Maiello, E., Milella, M., Pinto, C., Reni, M. & Tortora, G., Apr 21 2018, (Accepted/In press) In : Expert Review of Pharmacoeconomics and Outcomes Research. p. 1-12 12 p.Research output: Contribution to journal › Article
gemcitabine
Paclitaxel
Pancreatic Neoplasms
Cost-Benefit Analysis
Albumins
An Italian cost-effectiveness analysis of paclitaxel albumin (nab-paclitaxel) + gemcitabine vs gemcitabine alone for metastatic pancreatic cancer patients: the APICE study
Lazzaro, C., Barone, C., Caprioni, F., Cascinu, S., Falcone, A., Maiello, E., Milella, M., Pinto, C., Reni, M. & Tortora, G., Aug 2018, In : Expert Review of Pharmacoeconomics and Outcomes Research. 18, 4, p. 435-446 12 p.Research output: Contribution to journal › Article
gemcitabine
Paclitaxel
Pancreatic Neoplasms
Cost-Benefit Analysis
Albumins
An Italian cost-effectiveness analysis of paclitaxel albumin (nab-paclitaxel) + gemcitabine vs gemcitabine alone for metastatic pancreatic cancer patients: the APICE study
Lazzaro, C., Barone, C., Caprioni, F., Cascinu, S., Falcone, A., Maiello, E., Milella, M., Pinto, C., Reni, M. & Tortora, G., 2018, In : Expert Review of Pharmacoeconomics and Outcomes Research. 18, 4, p. 435-446 12 p.Research output: Contribution to journal › Article
gemcitabine
Paclitaxel
Pancreatic Neoplasms
Cost-Benefit Analysis
Albumins
A randomised phase 2 trial of nab-paclitaxel plus gemcitabine with or without capecitabine and cisplatin in locally advanced or borderline resectable pancreatic adenocarcinoma
Reni, M., Zanon, S., Balzano, G., Passoni, P., Pircher, C., Chiaravalli, M., Fugazza, C., Ceraulo, D., Nicoletti, R., Arcidiacono, PG., Macchini, M., Peretti, U., Castoldi, R., Doglioni, C., Falconi, M., Partelli, S. & Gianni, L., 2018, In : European Journal of Cancer. 102, p. 95-102 8 p.Research output: Contribution to journal › Article
gemcitabine
Cisplatin
Adenocarcinoma
Disease-Free Survival
Survival
Biomarker-driven and molecularly targeted therapies for pancreatic adenocarcinoma
Zhen, DB., Coveler, A., Zanon, S., Reni, M. & Chiorean, EG., 2018, In : Seminars in Oncology. 45, 3, p. 107-115 9 p.Research output: Contribution to journal › Article
Adenocarcinoma
Biomarkers
Hyaluronic Acid
Neoplasms
DNA Mismatch Repair